Similarly, CTX was shown to inhibit breast cancer by downregulating ERα expression levels, which suggests that CTX might disrupt a key pathway involved in breast cancer progression by interfering with the ERα signalling pathway (Wang et al. 2019). Here, ESR1 is linked to breast carcinoma.